---
title: "Some shareholders of Novoprotein plan to reduce their holdings by no more than 1.04%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/229409746.md"
description: "According to the Zhitong Finance APP, Novoprotein announced that its shareholders Nanjing Jinli Venture Capital Partnership (Limited Partnership) (referred to as \"Nanjing Jinli\") and Suzhou Jinling Venture Capital Partnership (Limited Partnership) (referred to as \"Suzhou Jinling\") plan to collectively reduce their holdings in the company by no more than 728,600 shares, accounting for 1.04% of the company's total share capital"
datetime: "2025-02-24T11:39:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/229409746.md)
  - [en](https://longbridge.com/en/news/229409746.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/229409746.md)
generator: "portal-rs"
---

# Some shareholders of Novoprotein plan to reduce their holdings by no more than 1.04%

According to the Zhitong Finance APP, Novoprotein (688137.SH) announced that its shareholders Nanjing Jinli Venture Capital Partnership (Limited Partnership) (referred to as "Nanjing Jinli") and Suzhou Jinling Venture Capital Partnership (Limited Partnership) (referred to as "Suzhou Jinling") plan to collectively reduce their holdings in the company by no more than 728,600 shares, accounting for 1.04% of the company's total share capital

### Related Stocks

- [688137.CN](https://longbridge.com/en/quote/688137.CN.md)

## Related News & Research

- [17:08 ETThe Inner Circle acknowledges Mary Helen Schrag, PT, OSC, Cert. MDT as a Pinnacle Professional of The Year](https://longbridge.com/en/news/296955805.md)
- [China Changbaishan International Holdings announces special general meeting](https://longbridge.com/en/news/296834310.md)
- [F3 Intersects Strong Alteration and Structure in 950 m Stepout from Tetra Zone | FUUFF Stock News](https://longbridge.com/en/news/296904518.md)
- [Gold Rallies to 3-Month High](https://longbridge.com/en/news/296629959.md)
- [Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate](https://longbridge.com/en/news/296689195.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**